Tibet Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume63,276 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TBET News and Ratings via Email

Sign-up to receive the latest news and ratings for Tibet Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Tibet Pharmaceuticals logo

About Tibet Pharmaceuticals

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women's anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. The company also develops Xuezang Guben pill indicated for the treatment of neurasthenia, insomnia, frequent urination, nocturnal emission, and women's menopausal symptoms; Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B. In addition, it focuses to commercialize Wupeng Pill for treating echimococosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. The company was formerly known as Shangri-La Tibetan Pharmaceuticals, Inc. and changed its name to Tibet Pharmaceuticals Inc. in July 2010. Tibet Pharmaceuticals, Inc. is headquartered in Wanchai, Hong Kong.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Medical Sector

2082nd out of 2,100 stocks

Pharmaceutical Preparations Industry

824th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Tibet Pharmaceuticals (OTCMKTS:TBET) Frequently Asked Questions

What stocks does MarketBeat like better than Tibet Pharmaceuticals?

Wall Street analysts have given Tibet Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tibet Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Tibet Pharmaceuticals' key executives?

Tibet Pharmaceuticals' management team includes the following people:
  • Mr. Hong Yu, Chairman and Chief Exec. Officer (Age 61)
  • Ms. Sabrina Y. Ren, Chief Financial Officer and Principal Accounting Officer (Age 49)

Who are some of Tibet Pharmaceuticals' key competitors?

What is Tibet Pharmaceuticals' stock symbol?

Tibet Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TBET."

How do I buy shares of Tibet Pharmaceuticals?

Shares of TBET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tibet Pharmaceuticals' stock price today?

One share of TBET stock can currently be purchased for approximately $0.01.

How many employees does Tibet Pharmaceuticals have?

Tibet Pharmaceuticals employs 190 workers across the globe.

Where are Tibet Pharmaceuticals' headquarters?

Tibet Pharmaceuticals is headquartered at 90 JAFFE ROAD ROOM 1701 17/F, WANCHAI K3, .

How can I contact Tibet Pharmaceuticals?

Tibet Pharmaceuticals' mailing address is 90 JAFFE ROAD ROOM 1701 17/F, WANCHAI K3, . The company can be reached via phone at 852 9798 5569.

This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.